Related Experiment Video
Updated: Jun 11, 2026
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
Association Between Renin-Angiotensin System Inhibitors and Antiseizure Medication Burden in Critically Ill Patients
Sophie Samuel1, A J Cadena-Tejada2, K Peoples2
1Department of Pharmacy, Memorial Hermann Hospital - Texas Medical Center, Houston, USA.
Background:
Status epilepticus (SE) often requires escalating antiseizure medication (ASM) therapy, increasing risks of hypotension, prolonged ventilation, and metabolic complications. The renin-angiotensin-aldosterone system (RAAS) has been implicated in neuronal excitability and neuroinflammation, yet its role in acute seizure management remains unclear.
Objective:
To evaluate the association between RAAS inhibitor exposure and ASM burden among critically ill adults with SE, and to assess treatment intensity based on total ASM administrations.
Methods:
We conducted a retrospective cohort study of adults with non-structural SE admitted to a tertiary neurocritical care unit between 2019 and 2024. Exposure was defined as administration of a RAAS inhibitor, angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), during the intensive care unit (ICU) stay. The primary outcome was ASM burden, defined as the number of distinct ASMs administered during the ICU course. Continuous electroencephalogram reports were reviewed for electrographic seizure activity during the first 48 hours of monitoring. Negative binomial regression with log-transformed length of stay as an offset estimated incidence rate ratios (IRRs). Models were adjusted for age, hypertension, diabetes, and SE type, and validated using inverse probability of treatment weighting (IPTW).
Results:
Among 77 patients (17 RAAS inhibitor exposed, 60 non-RAAS inhibitor), RAAS inhibitor exposure was associated with a lower ASM burden (unadjusted IRR = 0.45; 95% confidence interval 0.24-0.83, P = 0.01). The association remained directionally consistent after covariate adjustment (IRR = 0.71 [0.38-1.34], P = 0.31) and after IPTW weighting (IRR = 0.63 [0.35-1.16], P = 0.14). Electrographic seizures were absent in the RAAS inhibitor group during the first 48 hours of EEG monitoring.
Conclusions And Relevance:
RAAS inhibitor exposure was associated with lower ASM utilization in critically ill patients with SE, with consistent direction across adjusted models. These findings support further investigation into RAAS modulation as a potential neuroprotective mechanism in acute epileptic states.
Related Concept Videos
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System